Phase II Study of Bevacizumab (BEV), Temozolomide (TMZ) and Hypofractionated Stereotactic Radiotherapy (HFSRT) for Newly Diagnosed Glioblastoma (GBM)

被引：0
|
作者：
Beal, K. [1 ]
Omuro, A. [1 ]
Karimi, S. [1 ]
Correa, D. [1 ]
Chan, T. A. [1 ]
DeAngelis, L. M. [1 ]
Yamada, Y. [1 ]
Abrey, L. E. [1 ]
Gutin, P. H. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2011年 / 81卷 / 02期
关键词：
D O I：
10.1016/j.ijrobp.2011.06.266
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S129 / S129
页数：1
相关论文
共 50 条
  • [1] Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM).
    Omuro, A. M. P.
    Beal, K.
    Karimi, S.
    Correa, D.
    Chan, T. A.
    DeAngelis, L. M.
    Gavrilovic, I. T.
    Nolan, C.
    Hormigo, A.
    Lassman, A. B.
    Kaley, T. J.
    Mellinghoff, I. K.
    Grommes, C.
    Panageas, K.
    Reiner, A. S.
    Barradas, R.
    Abrey, L. E.
    Gutin, P. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [2] Phase II study of bevacizumab (BEV), temozolomide (TMZ), and hypofractionated stereotactic radiotherapy (HFSRT) for newly diagnosed glioblastoma (GBM).
    Omuro, A. A.
    Beal, K.
    Karimi, S.
    Chan, T. A.
    Panageas, K.
    Nayak, L.
    Seko, B.
    DeAngelis, L. M.
    Abrey, L. E.
    Gutin, P. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] PHASE II STUDY OF BEVACIZUMAB, TEMOZOLOMIDE, AND HYPOFRACTIONATED STEREOTACTIC RADIOTHERAPY (HFSRT) FOR NEWLY DIAGNOSED GLIOBLASTOMA
    Omuro, Antonio
    Beal, Kathryn
    Correa, Denise
    Chan, Timothy
    DeAngelis, Lisa
    Gavrilovic, Igor
    Nolan, Craig
    Hormigo, Adilia
    Lassman, Andrew B.
    Kaley, Thomas
    Mellinghoff, Ingo
    Grommes, Christian
    Panageas, Kathryn
    Reiner, Ann
    Barradas, Renata
    Abrey, Lauren
    Gutin, Philip
    NEURO-ONCOLOGY, 2011, 13 : 59 - 60
  • [4] Phase II Study of Bevacizumab, Temozolomide, and Hypofractionated Stereotactic Radiotherapy for Newly Diagnosed Glioblastoma
    Omuro, Antonio
    Beal, Kathryn
    Gutin, Philip
    Karimi, Sasan
    Correa, Denise D.
    Kaley, Thomas J.
    DeAngelis, Lisa M.
    Chan, Timothy A.
    Gavrilovic, Igor T.
    Nolan, Craig
    Hormigo, Adilia
    Lassman, Andrew B.
    Mellinghoff, Ingo
    Grommes, Christian
    Reiner, Anne S.
    Panageas, Katherine S.
    Baser, Raymond E.
    Tabar, Viviane
    Pentsova, Elena
    Sanchez, Juan
    Barradas-Panchal, Renata
    Zhang, Jianan
    Faivre, Geraldine
    Brennan, Cameron W.
    Abrey, Lauren E.
    Huse, Jason T.
    CLINICAL CANCER RESEARCH, 2014, 20 (19) : 5023 - 5031
  • [5] FLAIR, T1 contrast enhancement, MR perfusion, and FDG PET following hypofractionated stereotactic radiotherapy (HFSRT), bevacizumab (BEV), and temozolomide (TMZ) for glioblastoma (GBM).
    Grommes, C.
    Karimi, S.
    Beal, K.
    Chan, T. A.
    Abrey, L. E.
    Gutin, P. H.
    Omuro, A. M. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] Bevacizumab (BEV) in combination with temozolomide (TMZ) and radiation therapy (XRT) followed by BEV, TMZ, and irinotecan for newly diagnosed glioblastoma multiforme (GBM)
    Vredenburgh, J. J.
    Desjardins, A.
    Reardon, D. A.
    Peters, K.
    Kirkpatrick, J.
    Herndon, J. E.
    Marcello, J.
    Bailey, L.
    Threatt, S.
    Friedman, H. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials
    Carlson, Julie A.
    Reddy, Krishna
    Gaspar, Laurie E.
    Ney, Douglas
    Kavanagh, Brian D.
    Damek, Denise
    Lillehei, Kevin
    Chen, Changhu
    JOURNAL OF NEURO-ONCOLOGY, 2015, 123 (02) : 251 - 257
  • [8] Hypofractionated-intensity modulated radiotherapy (hypo-IMRT) and temozolomide (TMZ) with or without bevacizumab (BEV) for newly diagnosed glioblastoma multiforme (GBM): a comparison of two prospective phase II trials
    Julie A. Carlson
    Krishna Reddy
    Laurie E. Gaspar
    Douglas Ney
    Brian D. Kavanagh
    Denise Damek
    Kevin Lillehei
    Changhu Chen
    Journal of Neuro-Oncology, 2015, 123 : 251 - 257
  • [9] SAFETY RESULTS FROM AVAglio, A PHASE III RANDOMIZED STUDY OF BEVACIZUMAB (BEV) PLUS STANDARD COMBINATION TEMOZOLOMIDE (TMZ) AND RADIOTHERAPY (RT) IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM)
    Saran, Frank
    Chinot, Olivier L.
    Henriksson, Roger
    Mason, Warren
    Wick, Wolfgang
    Nishikawa, Ryo
    Dahr, Sunita
    Hilton, Magalie
    Garcia, Josep
    Cloughesy, Timothy
    NEURO-ONCOLOGY, 2013, 15 : 127 - 128
  • [10] A PILOT PHASE II TRIAL OF HYPOFRACTIONATED INTENSITY-MODULATED RADIATION THERAPY (hypo-IMRT) COMBINED WITH TEMOZOLOMIDE (TMZ) AND BEVACIZUMAB (BEV) FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA MULTIFORME (GBM)
    Ney, Douglas
    Carlson, Julie
    Damek, Denise
    Blatchford, Patrick
    Gaspar, Laurie
    Kavanagh, Brian
    Waziri, Allen
    Lillehei, Kevin
    Reddy, Krishna
    Chen, Changhu
    NEURO-ONCOLOGY, 2013, 15 : 80 - 81
12345